Latest Pharma Insights
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched - Clone
The US-India dance on pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
The US-India dance on pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched
The US-India dance around pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
The US-India dance around pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched - Clone
The US-India dance on pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
The US-India dance on pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched
The US-India dance around pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
The US-India dance around pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
Scrip - February 7, 2026
Bundling Approach Brings $382M Antitrust Verdict Against Medtronic
The medtech giant violated USA and California antitrust law in its sales practices for devices used to cut and seal blood vessels during surgery, a jury found. Rival firm Applied Medical brought the case.
Medtech Insight - February 6, 2026
The medtech giant violated USA and California antitrust law in its sales practices for devices used to cut and seal blood vessels during surgery, a jury found. Rival firm Applied Medical brought the case.
Medtech Insight - February 6, 2026
Global Medtech Guidance Tracker: January 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - February 6, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - February 6, 2026
Boston Scientific Says Penumbra Deal Could Lift Market Growth Profile As 10%+ Organic Target Holds
Boston Scientific also announced a new collaboration with Siemens Healthineers aimed at expanding its structural heart imaging capabilities. The companies plan to develop and commercialize a next-generation 4D intracardiac echocardiography catheter, ACUNAV.
Medtech Insight - February 6, 2026
Boston Scientific also announced a new collaboration with Siemens Healthineers aimed at expanding its structural heart imaging capabilities. The companies plan to develop and commercialize a next-generation 4D intracardiac echocardiography catheter, ACUNAV.
Medtech Insight - February 6, 2026
Boston Scientific Sees EP Growth Exceeding Market Despite PFA Competition
Boston Scientific exits 2025 with roughly a 65% share of the PFA market, within a segment the company believes will grow about 15%.
Medtech Insight - February 6, 2026
Boston Scientific exits 2025 with roughly a 65% share of the PFA market, within a segment the company believes will grow about 15%.
Medtech Insight - February 6, 2026
Abbott Says Plans To Launch Dual Diabetes Sensor Unimpeded By Latest Warning Letter
A warning letter from the US FDA citing concerns of some Abbott continuous glucose monitors will not stop the company from launching a novel diabetes sensor later this year as planned.
Medtech Insight - February 6, 2026
A warning letter from the US FDA citing concerns of some Abbott continuous glucose monitors will not stop the company from launching a novel diabetes sensor later this year as planned.
Medtech Insight - February 6, 2026
Industry View: Good Year Shaping For Regulatory Progress In The UK – And EU
With EU MDR/IVDR review proposals out, UK MHRA progress on a premarket regulation and, up ahead, a prospective consultation on accepting the CE marking indefinitely, now is a good time to assess EU-UK regulatory positions for the benefit of UK industry, says ABHI director Steve Lee.
Medtech Insight - February 6, 2026
With EU MDR/IVDR review proposals out, UK MHRA progress on a premarket regulation and, up ahead, a prospective consultation on accepting the CE marking indefinitely, now is a good time to assess EU-UK regulatory positions for the benefit of UK industry, says ABHI director Steve Lee.
Medtech Insight - February 6, 2026
Rhode Delivers: E.l.f. Beauty Posts Blowout Fiscal Q3 and Raises Full-Year Outlook
Oakland, Calif.-based E.l.f. Beauty Inc.’s reported sales in the fiscal third quarter soared 38% to $489.5m and its net income reached $39.4m, more than double what it achieved in the same period a year ago.
HBW Insight - February 6, 2026
Oakland, Calif.-based E.l.f. Beauty Inc.’s reported sales in the fiscal third quarter soared 38% to $489.5m and its net income reached $39.4m, more than double what it achieved in the same period a year ago.
HBW Insight - February 6, 2026
Self?Care’s Future: Will AI Agents Decide What Health Consumers Buy?
AI advisers could eventually guide consumers toward health products based on personalized needs rather than traditional marketing, IQVIA Consumer Health suggests. But brands will still need to balance data?driven recommendations with the human appeal of in?store discovery and self?care experiences.
HBW Insight - February 6, 2026
AI advisers could eventually guide consumers toward health products based on personalized needs rather than traditional marketing, IQVIA Consumer Health suggests. But brands will still need to balance data?driven recommendations with the human appeal of in?store discovery and self?care experiences.
HBW Insight - February 6, 2026
German Switch Committee Rejects Controversial Painkiller Metamizole
Germany’s Expert Committee for Prescription (SVA) has unanimously rejected the proposed switch of the controversial painkiller metamizole from prescription to OTC status.
HBW Insight - February 6, 2026
Germany’s Expert Committee for Prescription (SVA) has unanimously rejected the proposed switch of the controversial painkiller metamizole from prescription to OTC status.
HBW Insight - February 6, 2026
US FDA Explains: ‘Artificial’ Color Added To Food Doesn’t Equal Not Native To The Product
Agency exercises enforcement discretion on requirement for products to be labeled as containing artificial colors or dyes when those aren’t native to foods or ingredients, including added colors made from natural sources.
HBW Insight - February 6, 2026
Agency exercises enforcement discretion on requirement for products to be labeled as containing artificial colors or dyes when those aren’t native to foods or ingredients, including added colors made from natural sources.
HBW Insight - February 6, 2026
More America First Fees: US FDA Proposes GDUFA Facility Fee Waiver For Domestic Construction
The FDA wants to waive facility fees for three years if a sponsor breaks ground on a US-based manufacturing plant, but industry is concerned the idea will force other sponsors to subsidize competition.
Generics Bulletin - February 6, 2026
The FDA wants to waive facility fees for three years if a sponsor breaks ground on a US-based manufacturing plant, but industry is concerned the idea will force other sponsors to subsidize competition.
Generics Bulletin - February 6, 2026
Sandoz Enters Canadian Ophthalmology Market With Eylea Biosimilar
Sandoz’s aflibercept biosimilar Enzeevu launch in Canada comes just a few days after the firm signed a multiple asset deal, including an undisclosed ophthalmology product, with Alvotech, which recently gained immediate launch for its Eylea rival in the country.
Generics Bulletin - February 6, 2026
Sandoz’s aflibercept biosimilar Enzeevu launch in Canada comes just a few days after the firm signed a multiple asset deal, including an undisclosed ophthalmology product, with Alvotech, which recently gained immediate launch for its Eylea rival in the country.
Generics Bulletin - February 6, 2026
‘Access Is A Right, Not A Privilege’ – Medicines For Europe’s Saltofte Sets Out Priorities
After taking the reins as president of Medicines for Europe at the start of 2026, Zentiva CEO Steffen Saltofte sets out priorities for the group that include ensuring access to medicines, industry resilience and competitiveness, harmonized regulation, and sustainability for the off-patent sector.
Generics Bulletin - February 6, 2026
After taking the reins as president of Medicines for Europe at the start of 2026, Zentiva CEO Steffen Saltofte sets out priorities for the group that include ensuring access to medicines, industry resilience and competitiveness, harmonized regulation, and sustainability for the off-patent sector.
Generics Bulletin - February 6, 2026
Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
Generics Bulletin - February 6, 2026
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
Generics Bulletin - February 6, 2026
Update On ADCs: Sales, Deals, Targets And Approvals
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
In Vivo - February 5, 2026
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
In Vivo - February 5, 2026